人类乳头瘤病毒16,18型,p53基因与胃癌

３０例新鲜胃癌标本，采用多聚酶链反应技术检测人类乳头瘤病毒１６、１８感染、并采用多聚酶链反应－单链构象多态性技术对ｐ５３基因突变进行检测。结果：ＨＰＶ１５阳性率为４０．０％，未发现ＨＰＶ１８感染：Ｐ５３基因突变率为５０．０％，ＨＰＶ１６感染和Ｐ５３基因突变同时存在者为１６．７％。     

4666例妇女PCR检测HPV感染结果分析

目的:了解宫颈炎、宫颈及外阴赘生物、外阴疣等患者HPV感染的状况。方法:提取患者宫颈分泌物及脱落细胞、赘生物脱落细胞,用荧光定量PCR方法对提取物进行HPV6/11、HPV16/18检测。结果:4 666例患者中HPV感染率为25.50%;1 808例宫颈炎患者中HPV16/18型阳性率为13.38%;2 858例宫颈或外阴赘生物、外阴疣患者HPV6/11型阳性率为33.17%;228例同时接受了HPV6/11和HPV16/18型检测的患者中,有28例同时感染低危型及高危型乳头瘤病毒,占受检者的12.28%。结论:HPV在女性生殖道有较高的感染率,不同型别的乳头瘤病毒感染可导致不同的病变,HPV是影响女性生殖健康的重要危险因素;宫颈癌的年轻化与HPV感染低年龄段高感染率有密切关系;加强生殖健康宣传教育,提高性保健综合服务水平任重而道远。     

76例宫颈癌组织中人类乳头瘤病毒的检测

本文应用ＨＰＶ－ＰＣＲ技术和ＤＮＡ杂交技术对７６例宫颈鳞癌标本进行了ＨＰＶ－ＤＮＡ的研究，发现ＨＰＶ－ＤＮＡ存在率为９０．７９％（６９／７６），主要类型为ＨＰＶ１６和１８。多酶切ＳｏｕｔｈｅｒｎＢｌｏｔ杂交证实在宫颈癌中９２．５６％的ＨＰＶ－ＤＮＡ发生变异，说明ＨＰＶ－ＤＮＡ的基因变异与其致癌作用密切相关。ＰＣＲ结果证实ＨＰＶ－Ｅ６片段在宫颈癌组织中常可出现，推测可能是致癌的关键片段之一。因此，检测宫颈癌组织中ＨＰＶ－ＤＮＡ的完整性、关键基因片段的存在与否，可能对于病变恶变的预测有一定的意义     

Nucleic acid spot hybridization with nonradioactive labeled probes in screening for human papillomavirus DNA sequences

We examined 161 human tissue samples using the spot hybridization technique with nonradioactive labeled DNA probes of human papillomavirus (HPV). Whole cells were spotted on nitrocellulose filters; DNA of the cells was denatured and fixed to the filter. Then the DNA spots were hybridized to nonradioactive labeled DNA and monitored by a sandwich immunoenzymatic reaction. This technique is simple, sensitive, specific, requires no special equipment, and can be used in clinical settings. HPV DNA was found in 92% of samples in which, on the basis of histologic and colposcopic criteria, its presence was suspected, as well as in 31 samples where it was not suspected.     

Detection of human papillomavirus in organs of upper genital tract in women with cervical cancer

In this study, we evaluated the presence of human papillomavirus (HPV) DNA in organs of the female upper genital tract, using nine hysterectomy and salpingo-oophorectomy specimens affected by HPV-positive invasive cervical carcinomas, to establish if cervical HPV infection can spread to upper tracts of the female genital system. HPV DNA was evaluated by polymerase chain reaction (PCR) in all cervical carcinomas as well as in all tracts of the genital system. Then, these data were compared with the results obtained from PCR study of five other hysterectomy and salpingo-oophorectomy specimens (control cases). The criteria used for selection of the control cases were informed consent of the patients for research at the time of surgery, absence of neoplasms, absence of any anatomic lesion caused by HPV in cervix, and external genitalia. All selected cases were squamous cervical carcinomas. PCR analysis revealed HPV DNA in all cases of cervical carcinoma. The HPV DNA was detected as weak positivity on PCR analysis in other organs of the genital system. However, the distribution of HPV DNA varied in the various cases and in the different tracts of the same hysterectomy and salpingo-oophorectomy specimen. We believe that the HPV DNA, detected as a weakly positive signal, in the upper genital tract of patients who have a cervical squamous carcinoma could be a reflection of a latent HPV infection, as well as a sign of the existence of micrometastases containing HPV DNA, which cannot be detected by conventional histologic techniques.     

外阴尖锐湿疣人乳头瘤病毒感染的检测与分型

目的 了解患外阴尖锐湿疣人乳头瘤病毒(HPV)6型和11型的感染情况及PCR方法对尖锐湿疣诊断与分型的临床意义。方法 采用PCR方法测定160例尖锐湿疣患病题组织或分泌物中HPV6／11型及HPVl6／18型的感染率。结果 HPV6／11型感染率为95％(152／160)，HPVl6／18型感染率为5％(8／160)，HPV6／11型 HPVl6／18型混合感染率为1．3％(2／160)。结论 外阴尖锐湿疣患以HPV6型和11型感染为主。PCR方法是一种比较适合临床HPV检测与分型的极为敏感和特异的诊断方法。     

人乳头瘤病毒与呼吸道肿瘤关系的研究：Ⅰ.HPV与喉癌的关系

应用α－３２Ｐ－ｄＣＴＰ标记ＨＰＶ－１１及ＨＰＶ－１６ＤＮＡ为探针，以Ｓｌｏｔｂｌｏｔ及Ｓｏｕｔｈｅｒｎｂｌｏｔ两种核酸杂交技术，检测了取自青岛及北京两个地区的３７例喉鳞癌组织ＤＮＡ中ＨＰＶ－１１及ＨＰＶ－１６ＤＮＡ相关序列。结果表明，Ｓｌｏｔｂｌｏｔ杂交中，与ＨＰＶ－１１探针杂交阳性者占８６％（３２／３７），与ＨＰＶ－１６探针杂交阳性者占８１％（３０／３７）。在同一癌组织中，与两型探针同时呈现阳性者占８１％（３０／３７）。Ｓｏｕｔｈｅｒｎｂｌｏｔ杂交中，与所用探针ＤＮＡ的内切酶ＰｓｔⅠ酶切图谱比较，有４６％（１３／２８）与ＨＰＶ－１６ＤＮＡ的酶切图谱相同，可定为ＨＰＶ－１６型。当用ＨＰＶ－１１探针时无一例出现与ＨＰＶ－１１相同的图谱。提示喉癌的发生与ＨＰＶ－１６有关。     

尖锐湿疣患者人乳头瘤病毒的基因分型

目的 探索尖锐湿疣患者人乳头瘤病毒的基因分型。方法 PCR方法检测HPV6／11型、HPV16／18型DNA。结果 检测尖锐湿疣患者100例，对其中35例进行组织活检，阳性检出率为91．4％(32／35)，阳性检出中，HPV6／11型26例(81．2％)，HPV16／18型3例(9．4％)，HPV6／11 HPV16／18型3例(9．4％)；对其中65例进行宫颈抹片检测，阳性检出率为92．3％(60／65)，阳性检出中，HPV6／11型41例(68．3％)，HPV16／18型12例(20．0％)，HPV6／11 HPV16／18型7例(11．7％)。结论 尖锐湿疣患者人乳头瘤病毒感染以HPV6／11型为主，HPV16／18型在宫颈处感染率高于其它处组织。     

Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer

Human papilloma virus (HPV) type 16 infections of the genital tract are associated with the development of cervical cancer (CxCa) in women. HPV16-derived oncoproteins E6 and E7 are expressed constitutively in these lesions and might therefore be attractive candidates for T-cell-mediated adoptive immunotherapy. However, the low precursor frequency of HPV16E7-specific T cells in patients and healthy donors hampers routine isolation of these cells for adoptive transfer. To overcome this problem, we have isolated T cell receptor (TCR) genes from four different HPV16E7-specific healthy donor and patient-derived human cytotoxic T lymphocyte (CTL) clones. We examined whether genetic engineering of peripheral blood-derived CD8+ T cells in order to express HPV16E711-20-specific TCRs is feasible for adoptive transfer purposes. Reporter cells (Jurkat/MA) carrying a transgenic TCR were shown to bind relevant but not irrelevant tetramers. Moreover, these TCR-transgenic Jurkat/MA cells showed reactivity towards relevant target cells, indicating proper functional activity of the TCRs isolated from already available T cell clones. We next introduced an HPV16E711-20-specific TCR into blood-derived, CD8+ recipient T cells. Transgenic CTL clones stained positive for tetramers presenting the relevant HPV16E711-20 epitope and biological activity of the TCR in transduced CTL was confirmed by lytic activity and by interferon (IFN)-gamma secretion upon antigen-specific stimulation. Importantly, we show recognition of the endogenously processed and HLA-A2 presented HPV16E711-20 CTL epitope by A9-TCR-transgenic T cells. Collectively, our data indicate that HPV16E7 TCR gene transfer is feasible as an alternative strategy to generate human HPV16E7-specific T cells for the treatment of patients suffering from cervical cancer and other HPV16-induced malignancies.